AI Engines For more Details: Perplexity Kagi Labs You
Expectorant Action: Guaifenesin works by increasing the volume and reducing the viscosity (thickness) of respiratory tract secretions. This helps to loosen and thin mucus in the airways, making it easier to cough up and expel from the body.
Relief of Chest Congestion: Guaifenesin is effective in relieving chest congestion by promoting the clearance of mucus from the airways. It helps to alleviate symptoms such as coughing, wheezing, and difficulty breathing associated with excessive mucus production.
Treatment of Productive Cough: Guaifenesin is particularly beneficial for treating productive coughs (coughs that produce mucus or phlegm) by facilitating the removal of excess mucus from the respiratory tract. It can help to alleviate coughing and improve breathing in individuals with respiratory infections.
Non-Sedating: Unlike some other cough medications, guaifenesin does not typically cause drowsiness or sedation as a side effect. This makes it suitable for use during the day when alertness is required.
Combination Products: Guaifenesin is often included as an active ingredient in combination cold and cough medications, where it is combined with other ingredients such as decongestants, antihistamines, or analgesics to provide relief from multiple cold symptoms.
Available in Various Formulations: Guaifenesin is available in various formulations, including oral liquids, tablets, capsules, and extended-release formulations. This allows for flexible dosing options based on individual preferences and needs.
Over-the-Counter Availability: Guaifenesin is widely available without a prescription and can be purchased over the counter at pharmacies and retail stores. It is often recommended as a first-line treatment for cough and chest congestion.
Minimal Side Effects: Guaifenesin is generally well-tolerated, and side effects are rare. However, some individuals may experience mild gastrointestinal upset, such as nausea, vomiting, or stomach discomfort, particularly at higher doses.
Hydration: Adequate hydration is important when taking guaifenesin to maximize its effectiveness. Drinking plenty of fluids helps to thin mucus further and promote its clearance from the respiratory tract.
Caution in Certain Populations: While guaifenesin is considered safe for most adults and children, it should be used with caution in individuals with certain medical conditions, such as kidney disease or a history of gastrointestinal ulcers. Pregnant or breastfeeding women should consult a healthcare professional before using guaifenesin.
Drug Interactions: Guaifenesin is not known to interact significantly with other medications. However, it is always important to consult a healthcare provider or pharmacist before using guaifenesin if you are taking other medications to ensure there are no potential interactions.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 2.2 | 0.3 | 6.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 1.6 | 1.2 | 0.33 |
| Allergies | 2.3 | 1 | 1.3 |
| Allergy to milk products | 1.1 | 1.2 | -0.09 |
| Alopecia (Hair Loss) | 0.4 | 0.4 | |
| Alzheimer's disease | 3 | 4.4 | -0.47 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.3 | 0.5 | 1.6 |
| Ankylosing spondylitis | 2.1 | 0.6 | 2.5 |
| Anorexia Nervosa | 1 | 2 | -1 |
| Antiphospholipid syndrome (APS) | 1 | 0.3 | 2.33 |
| Asthma | 2.5 | 1.5 | 0.67 |
| Atherosclerosis | 1.5 | 1.2 | 0.25 |
| Atrial fibrillation | 1.5 | 1.5 | 0 |
| Autism | 3.9 | 3.5 | 0.11 |
| Autoimmune Disease | 1.2 | 0.8 | 0.5 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.8 | 0.8 | |
| Bipolar Disorder | 1.8 | 1.1 | 0.64 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.2 | 0.2 | |
| Cancer (General) | 0.3 | 0.6 | -1 |
| Carcinoma | 3 | 1.6 | 0.88 |
| Celiac Disease | 1.8 | 1.6 | 0.13 |
| Cerebral Palsy | 0.9 | 1.3 | -0.44 |
| Chronic Fatigue Syndrome | 2.5 | 1.4 | 0.79 |
| Chronic Kidney Disease | 1.8 | 1.2 | 0.5 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | 0.8 | 0 |
| Chronic Urticaria (Hives) | 1.1 | 0.2 | 4.5 |
| Coagulation / Micro clot triggering bacteria | 1.1 | 1.3 | -0.18 |
| Cognitive Function | 1.5 | 1.4 | 0.07 |
| Colorectal Cancer | 3.7 | 1.6 | 1.31 |
| Constipation | 1.2 | 0.7 | 0.71 |
| Coronary artery disease | 1.7 | 1.4 | 0.21 |
| COVID-19 | 3.8 | 3.8 | 0 |
| Crohn's Disease | 4.1 | 2.3 | 0.78 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.8 | 1.3 | -0.63 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 1 | 1.4 | -0.4 |
| Denture Wearers Oral Shifts | 0.3 | 0.3 | |
| Depression | 5.3 | 4.2 | 0.26 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 0.9 | 0.8 | 0.13 |
| Endometriosis | 1.8 | 1.3 | 0.38 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 2.2 | 0.7 | 2.14 |
| erectile dysfunction | 0.9 | 0.3 | 2 |
| Fibromyalgia | 1.3 | 0.7 | 0.86 |
| Functional constipation / chronic idiopathic constipation | 3.2 | 2.1 | 0.52 |
| gallstone disease (gsd) | 1.4 | 0.8 | 0.75 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.3 | -0.5 |
| Generalized anxiety disorder | 1.8 | 0.9 | 1 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.7 | 1.7 | |
| Graves' disease | 1.2 | 2.1 | -0.75 |
| Gulf War Syndrome | 0.4 | 0.5 | -0.25 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 1.8 | 1 | 0.8 |
| Heart Failure | 1.7 | 1.3 | 0.31 |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| High Histamine/low DAO | 0.7 | 0.6 | 0.17 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
| hyperglycemia | 0.8 | 0.7 | 0.14 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 2.3 | 3.2 | -0.39 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 1.4 | 0.3 | 3.67 |
| IgA nephropathy (IgAN) | 1.2 | 1.2 | 0 |
| Inflammatory Bowel Disease | 3.4 | 3.6 | -0.06 |
| Insomnia | 0.7 | 1.6 | -1.29 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 0.7 | 0.3 | 1.33 |
| Irritable Bowel Syndrome | 3.5 | 2.4 | 0.46 |
| ischemic stroke | 1.5 | 1.4 | 0.07 |
| Liver Cirrhosis | 4.1 | 2.2 | 0.86 |
| Long COVID | 2.7 | 2.9 | -0.07 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 1.2 | 0.4 | 2 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.6 | 0.5 |
| ME/CFS with IBS | 0.3 | 0.6 | -1 |
| ME/CFS without IBS | 0.9 | 0.6 | 0.5 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.6 | 0.5 | 0.2 |
| Metabolic Syndrome | 4.6 | 3.3 | 0.39 |
| Mood Disorders | 5.1 | 3.5 | 0.46 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.1 | 2 |
| Multiple Sclerosis | 3.1 | 2 | 0.55 |
| Multiple system atrophy (MSA) | 0.8 | 0.7 | 0.14 |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 0.3 | 1.4 | -3.67 |
| Neuropathy (all types) | 0.7 | 1.2 | -0.71 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.1 | 2 | 0.55 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 4.7 | 3.2 | 0.47 |
| obsessive-compulsive disorder | 2 | 1.4 | 0.43 |
| Osteoarthritis | 1.4 | 1.2 | 0.17 |
| Osteoporosis | 2 | 0.7 | 1.86 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 4 | 3.1 | 0.29 |
| Polycystic ovary syndrome | 2.7 | 2.4 | 0.13 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.7 | 0.7 | |
| primary biliary cholangitis | 0.3 | 0.7 | -1.33 |
| Primary sclerosing cholangitis | 0.9 | 0.5 | 0.8 |
| Psoriasis | 1.7 | 0.8 | 1.13 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.6 | 2 | 0.8 |
| Rosacea | 0.7 | 0.5 | 0.4 |
| Schizophrenia | 2.7 | 1.6 | 0.69 |
| scoliosis | 0.2 | 0.6 | -2 |
| Sjögren syndrome | 1.3 | 0.9 | 0.44 |
| Sleep Apnea | 0.7 | 1.6 | -1.29 |
| Slow gastric motility / Gastroparesis | 0.8 | 0.3 | 1.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | 0.8 | |
| Stress / posttraumatic stress disorder | 1.3 | 1.7 | -0.31 |
| Systemic Lupus Erythematosus | 2.3 | 1.6 | 0.44 |
| Tic Disorder | 0.9 | 0.6 | 0.5 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 2.3 | 1.8 | 0.28 |
| Type 2 Diabetes | 4.5 | 2.5 | 0.8 |
| Ulcerative colitis | 2 | 3 | -0.5 |
| Unhealthy Ageing | 1.4 | 1.1 | 0.27 |
| Vitiligo | 1.3 | 0.3 | 3.33 |
